DK0837935T3 - Den 3'-ikke-translaterede region af det humane prohibitin-gen - Google Patents

Den 3'-ikke-translaterede region af det humane prohibitin-gen

Info

Publication number
DK0837935T3
DK0837935T3 DK96921425T DK96921425T DK0837935T3 DK 0837935 T3 DK0837935 T3 DK 0837935T3 DK 96921425 T DK96921425 T DK 96921425T DK 96921425 T DK96921425 T DK 96921425T DK 0837935 T3 DK0837935 T3 DK 0837935T3
Authority
DK
Denmark
Prior art keywords
untranslated region
prohibitin gene
human prohibitin
human
gene
Prior art date
Application number
DK96921425T
Other languages
English (en)
Inventor
Orco Robert T Dell
Eldon R Jupe
J Keith Mcclung
Xiao-Tie Liu
Robert L King
Original Assignee
Oklahoma Med Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Med Res Found filed Critical Oklahoma Med Res Found
Application granted granted Critical
Publication of DK0837935T3 publication Critical patent/DK0837935T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
DK96921425T 1995-06-07 1996-06-07 Den 3'-ikke-translaterede region af det humane prohibitin-gen DK0837935T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/473,486 US5922852A (en) 1995-06-07 1995-06-07 3' untranslated region of the human prohibitin gene
PCT/US1996/009687 WO1996040919A1 (en) 1995-06-07 1996-06-07 3' utr of the human prohibitin gene

Publications (1)

Publication Number Publication Date
DK0837935T3 true DK0837935T3 (da) 2003-12-15

Family

ID=23879728

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96921425T DK0837935T3 (da) 1995-06-07 1996-06-07 Den 3'-ikke-translaterede region af det humane prohibitin-gen

Country Status (9)

Country Link
US (3) US5922852A (da)
EP (1) EP0837935B1 (da)
AT (1) ATE247709T1 (da)
AU (1) AU713814B2 (da)
CA (1) CA2224014A1 (da)
DE (1) DE69629570T2 (da)
DK (1) DK0837935T3 (da)
ES (1) ES2205046T3 (da)
WO (1) WO1996040919A1 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922852A (en) * 1995-06-07 1999-07-13 Oklahoma Medical Research Foundation 3' untranslated region of the human prohibitin gene
AU774116B2 (en) * 1995-06-07 2004-06-17 Oklahoma Medical Research Foundation Use of prohibitin RNA in treatment of cancer
AU723400B2 (en) * 1996-11-07 2000-08-24 Oklahoma Medical Research Foundation Diagnostic assay for breast cancer susceptibility
JP2002502584A (ja) * 1997-11-06 2002-01-29 オゥクラホゥマ、メディカル、リサーチ、ファウンデイシャン 癌罹患性の診断アッセイ
JP2002522014A (ja) * 1998-07-24 2002-07-23 オクラホマ メディカル リサーチ ファウンデーション 癌治療におけるプロヒビチンｒｎａの使用法
AU761027B2 (en) * 1998-08-25 2003-05-29 Merck Patent Gmbh Expression and export of angiostatin and endostatin as immunofusis
US7273855B2 (en) * 1999-07-24 2007-09-25 Oklahoma Medical Research Foundation Use of prohibitin RNA in treatment of cancer
US20040002071A1 (en) * 2001-09-19 2004-01-01 Intergenetics, Inc. Genetic analysis for stratification of cancer risk
CA2514184C (en) 2003-01-21 2016-04-12 Ptc Therapeutics, Inc. Methods for identifying compounds that modulate untranslated region-dependent gene expression and methods of using same
US8426194B2 (en) 2003-01-21 2013-04-23 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating VEGF expression
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
US20060246451A1 (en) * 2003-03-19 2006-11-02 Russell James A Plasminogen activator inhibitor-1 (pai-1) haplotypes useful as indicators of patient outcome
JP2006521116A (ja) * 2003-03-27 2006-09-21 ピーティーシー セラピューティクス，インコーポレーテッド 抗真菌性および／または抗増殖性分子を同定するためのｔＲＮＡスプライシング経路の酵素の標的化
EP1613159A4 (en) * 2003-03-27 2007-08-01 Ptc Therapeutics Inc METHODS OF IDENTIFYING COMPOUNDS TARGETING THE RNA THREADING ENDONUCLEASE AND USING THE SAME AS ANTIFUNGAL AGENTS
US20070020630A1 (en) * 2003-03-27 2007-01-25 Trotta Christopher R Methods of identifying compounds that target trna splicing endonuclease and uses of said compounds as anti-proliferative agents
EP1649002A4 (en) * 2003-07-02 2009-06-03 Ptc Therapeutics Inc RNA PROCESSING PROTEIN COMPLEXES AND USES THEREOF
CA2546363A1 (en) * 2003-11-17 2005-06-02 Anuradha Mehta Methods and agents for screening for compounds capable of modulating her2 expression
US8283115B1 (en) 2007-06-20 2012-10-09 Ptc Therapeutics, Inc. Methods of screening for compounds for treating muscular dystrophy using UTRN mRNA translation regulation
US8283116B1 (en) 2007-06-22 2012-10-09 Ptc Therapeutics, Inc. Methods of screening for compounds for treating spinal muscular atrophy using SMN mRNA translation regulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05271294A (ja) * 1992-01-24 1993-10-19 Japan Found Cancer Res ヒトプロヒビチンおよびそれをコードするｄｎａ
US5922852A (en) * 1995-06-07 1999-07-13 Oklahoma Medical Research Foundation 3' untranslated region of the human prohibitin gene

Also Published As

Publication number Publication date
US5776738A (en) 1998-07-07
ATE247709T1 (de) 2003-09-15
AU6265396A (en) 1996-12-30
DE69629570D1 (de) 2003-09-25
WO1996040919A1 (en) 1996-12-19
CA2224014A1 (en) 1996-12-19
AU713814B2 (en) 1999-12-09
DE69629570T2 (de) 2004-06-17
EP0837935A1 (en) 1998-04-29
ES2205046T3 (es) 2004-05-01
EP0837935B1 (en) 2003-08-20
US7259251B1 (en) 2007-08-21
US5922852A (en) 1999-07-13

Similar Documents

Publication Publication Date Title
DK0837935T3 (da) Den 3'-ikke-translaterede region af det humane prohibitin-gen
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
GEP20032897B (en) Epothilone Derivatives
NZ332720A (en) Therapeutic uses of bactericidal/permeability increasing (BPI) protein to treat human meningococcemia
KR970704430A (ko) 전립선 질환, 자궁내막증 및 비만증의 치료를 위한 드롤록시펜의 용도(use of droloxifene for the treatment of prostatic diseases endometriosis and obesity)
TR199901417T2 (xx) Analjezik etkisi olan yeni bile�imler.
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
NO994014D0 (no) Arylsulfonamider og analoger derav og deres anvendelse for behandling av neurodegenerative sykdommer
DE69322076D1 (de) S-triazin-derivate und diese als aktiven wirkstoff enthaltende heilmittel gegen östrogen abhängige krankheiten
DE122011100032I1 (de) Verwendung von n-substituierten pyridonen als tumornekrose-faktor alpha hemmer.
KR950700749A (ko) 2'-할로메틸리덴 유도체와 S-기 또는 M-기 특이성 항종양제를 사용하는 결합치료에 의한 암치료 방법(Method of treating cancer by conjunctive therapy with 2'-halomethylidene derivatives and a S-phase or M phase specific antineoplastic agent)
DE69620691T2 (de) Therapeutisches Mittel zur Behandlung der Hypercholesterinämie
NO931413D0 (no) Fremgangsmaater og preparater for behandling av celleproliferasjonssykdommer
DE69612056T2 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
FI973185A0 (fi) Melatoniinin käyttö lääkeriippuvuudesta kärsivien potilaiden hoitoon
DE69711779D1 (de) Neue Melatonin-Derivaten als Wirkstoff gegen freien Radikale sowie diese enthaltende Präparate
NO964330L (no) Farmasöytisk sammensetning for terapeutisk behandling av tardiv dyskinesi og anvendelse derav
GEP20012489B (en) Use of Natural Human α-Interferon
DE69321096D1 (de) Katecholamine-diphosphate und diese enthaltende arzneimittel
ES2181160T3 (es) Derivados de 1,4-dihidropiridina y su utilizacion en terapia.
ATE271878T1 (de) Verwendung von protein h als zytostattischer wirkstoff
DK0979093T3 (da) Terapeutisk virusmiddel, hvis udvikling kan standses
SE9503044D0 (sv) Antibodies for use in cancer therapy and diagnosis